SourceOne brings high potency citrus limonoids to US

SourceOne Global Partners is introducing high-potency citrus limonoids to the US market, developed using new technology that has made their production commercially viable, says the firm.

Citrus limonoids are highly oxygenated phytochemical compounds that occur naturally in citrus fruit, which have been investigated for their anti-viral, anti-fungal, anti-bacterial and anti-malarial powers.

In addition, they are thought to help support heart health and reduce the risk of cancer via their cholesterol-lowering, triglyceride lowering, anti-inflammatory and anti-oxidant properties, explained SourceOne CEO Jesse Lopez.

Exclusive distribution

Under a new deal with an existing partner, SourceOne has exclusive distribution of the new citrus limonoids in the US. The compounds are developed by Ingredients By Nature, using a technology that allows it to prepare the citrus derivatives at high concentrations.

According to SourceOne, the products have a potency of up to 98 percent, making them the “highest-potency citrus limonoids available in the marketplace”.

“Limonoids have been very difficult to extract and concentrate. The advanced technology that Ingredients By Nature has developed allows us to concentrate them and take them to market on a more commercially viable scale,” Lopez told NutraIngredients-USA.com.

Form and dosage

The ingredients, which are part of the Testlab line of products, come in powder form and can be used in supplement, food and beverage applications. Dosage levels vary according to application, but SourceOne recommends levels ranging between 100 and 300mg.

Ingredients By Nature has traditionally focused on citrus bioflavonoids, with a goal of deconstructing a citrus fruit, focusing on key citrus components and reassembling those into ‘superfruit’ extracts, said Lopez.

Citrus components it has focused on include bioflavonoids, polymethoxylated flavones (PMFs), HO PMFs and limonoids.

According to Lopez, the limonoids can be used synergistically with PMFs.